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We have developed a replication-competent human immunodeficiency virus (HIV) carrying a selective marker that can be
used in vivo. This recombinant virus (Z6 D nef gpt) was generated by replacing the 59 half of the HIV nef gene with the
Escherichia coli guanine phosphoribosyl transferase gene (gpt). This new vector can express the gpt product on infection and
works as a positive selective marker for mycophenolic acid (MPA) resistance, a potent immunosuppressive drug used in
organ rejection therapy. Conversely, gpt expression also served as a negative selectable marker, since its intracellular
expression induces host-cell susceptibility to 6-thioxantine (6-TX), a nucleotide analog that is toxic to the infected cell under
these conditions. In this manner, we could suppress the recombinant virus replication through 6-TX selection in both
transformed cells and primary human peripheral blood mononuclear cells (PBMCs), suggesting the vector’s potential as a
model for a new live-attenuated vaccine approach against HIV. © 2000 Academic Press
s
xINTRODUCTION
Live-attenuated vaccines have been used successfully
as powerful tools to combat infectious diseases since
the 1700s. Improvements in a smallpox live-attenuated
vaccine developed by Jenner in 1796 led to the eventual
eradication of this disease in 1972. A live-attenuated
vaccine for the human immunodeficiency virus has been
proposed (Desrosiers, 1992) based on a nef-deleted HIV
(Kestler et al., 1991). This vaccine approach has been
found to be safe and effective in adult rhesus monkeys
(Daniel et al., 1992) inoculated with a nef-deleted simian
immunodeficiency virus (SIV). However, some nef-de-
leted vaccine strains as well as multiple-deleted SIV
have been found to cause disease in inoculated new-
born macaques or even adult animals (Baba et al., 1995,
1999). Additionally, in some adult macaques, the deleted
gene can be restored in vivo and induce immunodefi-
ciency (Stahl-Hennig et al., 1996).
In the Sidney Blood Bank Cohort, a blood donor and
eight transfusion recipients were infected before 1985
with a strain of HIV-1 with a deletion in the region in
which the nef gene and the long terminal repeat overlap.
The five surviving recipients remain asymptomatic 14 to
18 years after HIV-1 infection without any antiretroviral
therapy; however, the donor began therapy only in Feb-
1 To whom correspondence and reprint requests should be ad-
ressed at Departamento de Genetica, CCS, Bloco Ac, Ilha do Fundao,aniversidade Federal do Rio de Janeiro, 21944–970 R J, Brazil. Fax: 5521
800994. E-mail: lavimoan@hotmail.com.
79ruary 1999 (Greenough et al., 1999; Learmont et al., 1999).
These facts highlight concerns about this approach and
challenge the scientific community to develop a safer
live-attenuated preventive vaccine.
Recently, researchers have developed new candidate
live-attenuated vaccines for HIV by introducing a “sui-
cide” gene into the HIV-1 genome (Chakrabarti et al.,
1996; Smith et al., 1996). In these models, ganciclovir
(GCV)-sensitive HIV-1 recombinant viruses were con-
structed by replacing half of the nef reading frame with
the herpes simplex virus type I (HSV-1) thymidine kinase
(tk) gene. GCV treatment of cells infected with HIV-tk
effectively prevented virus spread in human cell cultures
and in hu-PBL-SCID mice. Following a similar approach,
the main goal of this work was to develop a strategy that
can be used in an alternative candidate live-attenuated
vaccine for HIV carrying a new suicide gene. For that, we
chose to replace the HIV nef gene with the xanthine
guanine phosphoribosyl transferase (GPT) (Mulligan et
al., 1980), a bacterial analog of the mammalian enzyme
hypoxanthine phosphoribosyl transferase (HPRT). This
bacterial enzyme can be used as either a positive or
negative selective marker and has reduced toxicity to
mammalian cells. GPT has a high affinity for xanthine,
whereas HPRT cannot metabolize this purine. It is there-
fore possible to select for gpt expression in HPRT-ex-
pressing cells (HPRT1) by inhibition of de novo purine
ynthesis with mycophenolic acid (MPA) and inclusion of
anthine as a purine substrate (Mulligan et al., 1981). It is
1lso possible to select against gpt expression in HPRT
primary cells by taking advantage of the differential sub-
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80 TANURI ET AL.strate specificity of the two enzymes and using 6-thio-
xanthine (6-TX) as a counter-selective agent. Under these
conditions, GPT will phosphorylate this nucleoside ana-
log and the cell will metabolize it to 6-thioguanine, a
powerful toxic purine that blocks cellular-DNA replication
(Besnard et al., 1987). Such recombinant virus could be
used as a safer live-attenuated HIV-1 vaccine, since the
vaccine strain could be abrogated with 6-TX treatment if,
for any reason, the vaccinees develop AIDS symptoms.
Here, we document the construction of a recombinant
HIV-1 that carries the E. coli gpt gene, replacing the viral
nef gene. On infection, this virus induced the expression
of the bacterial enzyme and transduced resistance to
MPA. Lymphocytic cell lines carrying a proviral copy of
this recombinant HIV-1 were 6-TX sensitive. Moreover,
6-TX can abrogate the replication of the recombinant
virus in human PBMCs.
RESULTS
Biological characterization of Z6 D nef gpt
The manipulation of the 39 end of the genome did not
interfere with the normal replicative cycle of HIV, as
demonstrated by the viral kinetics posttransfection be-
tween Z6 and both constructs (Z6 D nef gpt and Z6 fsnef;
ee Fig. 1). The supernatant containing 104 TCID50 units
rom the transfection was used to infect PM-1 CD41
T-cells, permissive to both T- and M-tropic virus, with a
m.o.i. of 0.1. The Z6 D nef gpt virus replicated rapidly and
reached peak titers by 12 days postinfection, once again
generating a viral replication curve similar to that of Z6
and its nef (2) counterpart (Z6 fsnef; data not shown).
PM-1 cells infected with Z6 D nef gpt produced a 17.0-
kDa protein specifically recognized by antibody against
E. coli gpt peptide in an immunoprecipitation reaction
Fig. 2). The recombinant enzyme could be detected from
FIG. 1. COS-7 cells transfected with 1 mg of Z6, Z6 fsNEF, and Z6D nef
gpt infectious clones. The cells were maintained for 7 days and HIV p24
antigen production was measured.to 25 days postinfection. A natural enzyme extracted
rom the cytosolic fraction of an E. coli strain harboringpMSG plasmid was included in the immunoprecipitation
reaction and could also be recognized by the antiserum,
showing the same migration in the SDS–PAGE (Fig. 2,
lane 2).
The viral replication was also studied in human PB-
MCs, using 104 TCID50 of Z6, Z6 fsnef, or Z6 D nef gpt to
infect 5 3 105 activated PBMCs. The infection kinetics of
these three viruses were similar (Fig. 3A) and the genetic
stability of the Z6 D nef gpt virus was analyzed by PCR
amplification of the 39 end of provirus generated after
four serial passages in hu-PBMCs (Fig. 3B). This virus
proved to carry a genetically stable gpt gene insertion,
with an expected 1143-bp PCR product being visualized
in agarose gel throughout the time in culture. Generation
of MPA resistance was tested in PM-1 cells infected with
the Z6 D nef gpt virus. The survival curve showing the
PA selection in PM-1 cells infected with Z6, Z6 fs nef,
nd Z6 D nef gpt is depicted in Fig. 4. The mock-infected
PM-1 cell had an IC50 of 0.15 mg/ml, contrasting with the
same cell line infected with Z6 or Z6 fsNEF that showed
a lower IC50 (0.03 mg/ml). The PM-1 cells infected with
Z6 D nef gpt were more resistant to MPA, reaching an
IC50 of 1.5 mg/ml, nearly 50-fold higher than that found
or cells infected with HIV not expressing the resistance
ene.
brogation of HIV D nef gpt replication by 6-TX
At a wide range of concentrations, 6-TX is innocuous
o eucaryotic cells. The E. coli gpt gene monophosphor-
lates 6-TX with a high specific activity. Cellular enzymes
hen convert 6-TX-monophosphate to 6-thioguanine-
onophosphate, an effective terminator of DNA synthe-
FIG. 2. Autoradiogram showing the immunoprecipitation of biotin-
labeled protein of Z6, Z6 fsNEF, and Z6 D nef gpt extracted from
PM-1-infected cells using a polyclonal antibody against a 15-mer syn-
thetic peptide representing the N-terminal of the E. coli GPT. Lanes: 1,
ock-infected; 2, PM-1 protein extract spiked with 1 mg of E. coli DH5a
cytosolic extract; 3, Z6 fsNEF 10 days postinfection; 4 to 7, Z6 D nef gpt
5, 10, 20, and 25 days postinfection, respectively. The position of
migration of the molecular weight marker is depicted in the right side
of the gel and a band of the predicted molecular weight, 17 kDa, is
indicated by an arrow.
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81IN VIVO SELECTABLE HIV-1sis. To test the ability of 6-TX to inhibit proliferation of
PM-1 cells infected with Z6 D nef gpt, we cloned (by
imiting dilution) a culture of PM-1 cells resistant to 2
mg/ml of MPA following E. coli gpt transduction through
FIG. 3. Growth kinetics and genetic stability in human PBMC. PBMCs
for 25 days; and HIV p24 antigen production was measured (A). Vert
squares, or filled triangles) of three p24 determinations. Genetic stabilit
x axis shows the number of viral passages corresponding to the time o
of Z6 and Z6 D nef gpt was performed by isolating the proviral DNA fro
PCR products were separated on 1.4% TBE–agarose gel. Lane 1: X174
right side of the figure); lanes 2 and 3: control fragments generated wi
from the amplification of proviral DNA of Z6 D nef gpt-infected hu-PBM
9: PCR negative control.
FIG. 4. Survival of PM-1 cells in the presence of mycophenolic acid
MPA) and the effect of infection with Z6 and Z6-recombinant viruses.
he supernatant containing 104 TCID50 units from Z6, Z6 fsNEF, and Z6
nef gpt was used to infect PM-1 cells in a m.o.i. of 0.1. PM-1
ock-infected cells were also used as a control in the experiment. The
ells were cultivated for 10 days in RPMI media and expanded every 5
ays before exposure to the selective media. The cells (104) were
inoculated in a 24-well plate containing 1 ml of MPA media with
different concentrations of MPA (from 0 to 10 mg/ml). The cells were
cultivated and the media changed every 3 days; after 15 days, the
number of viable cells were counted and plotted. The percentage of
survival is always related to the cell counts in the well without the drug
(100% survival).Z6 D nef gpt infection. One clone (No. 37) was cultivated
in various concentrations of 6-TX. This cell line carries
one copy of Z6 D nef gpt proviral sequence per genome.
or this clone, cell growth could be totally inhibited with
00 mg/ml of the analog; in contrast, growth of wild-type
PM-1 cells was not affected at these drug concentrations
(Fig. 5).
Similarly, we tested the potential of 6-TX to inhibit the
Z6 D nef gpt virus replication in human PBMCs. In this
infected with Z6, Z6 fsNEF, and Z6 D nef gpt; the cells were maintained
s represent the SD of the average (plotted as filled diamonds, filled
D nef gpt was determined after four passages in hu-PBMCs. The upper
ion showed on the lower x axis. PCR analysis (B) of the 39-end regions
cted cells after each passage and using primers nef 102 and nef 103.
d with HaeIII (molecular weight markers indicated in kilobases on the
(934 bp) and pZ6 gpt (1134 bp); lanes 4 to 8: PCR products generated
e first, second, third, fourth, and fifth passages, respectively; and lane
FIG. 5. 6-TX treatment can kill PM-1 cells infected with Z6 D nef gpt.
Clone 37 was inoculated in 6-TX media with different concentrations of
6-thioxanthine (from 0 to 200 mg/ml). The cells were cultivated and the
media changed every 3 days; after 15 days, the number of viable cells
were counted and plotted. PM-1 cells were used as a control in thiswere
ical bar
y of Z6
f infect
m infe
digeste
th pZ6experiment. The percentage of survival is always related to the cell
counts of the well without the drug (100% survival).
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82 TANURI ET AL.case, 104 TCID50 of the Z6 D nef gpt virus was used to
nfect 5 3 105 human PBMCs. Cells were cultivated with
00 mg/ml of 6-TX. Fresh, activated human PBMCs were
added to the culture every 5 days, replacing half of the
culture volume, and p24 production was followed for 40
days (Fig. 6). A considerable inhibition was seen in this
experiment, and only a residual growth of the recombi-
nant virus could be observed. The drug was removed on
Day 25, and the culture was continued for another 20
days with no rebounding of the Z6 D nef gpt virus (Fig. 6).
PCR was used to detect the presence of Z6D nef gpt
proviral sequence in this culture. The PCR signal was not
detected after 10 days postinfection, nor even after the
selective pressure was withdrawn on Day 25. In contrast,
the same viral culture in nonselective media was PCR
positive and the signal could be easily visualized even
after 40 days in culture (data not shown). The replication
of Z6 fsnef and that of wild-type Z6 in human PBMCs
were not affected by 6-TX, even when the cells were
exposed to high doses of this compound (data not
shown).
DISCUSSION
Retroviral vectors efficiently transfer gene sequences
into cells and promote their stable expression. Recently,
HIV has been used as a replication-competent vector for
the expression of reporter genes such as chloramphen-
icol acetyltransferase (Terwilliger et al., 1989) and lucif-
erase (Chen et al., 1994; Connor et al., 1995). Other HIV
recombinants have been used to study the function of
viral genes (Wang and Barklis, 1993) or antiviral com-
FIG. 6. 6-TX treatment abolishes a spreading infection in hu-PBMCs.
The supernatant containing 104 TCID50 of Z6 D nef gpt virus was used
to infect 5 3 105 huPBMCs. The culture was cultivated with 100 mg/ml
f 6-TX (a drug concentration that inhibits 100% of the cell growth in
M-1 Z6 D nef gpt clone 37). Fresh, activated huPBMCs were added to
he culture every 5 days, replacing half of this culture media. The 6-TX
edia was removed 25 days postinfection, and the culture continued
ith RPMI media for an additional 15 days; HIV p24 antigen production
as measured (see arrow). A culture that had been similarly infected
nd maintained in RPMI media (without 6-TX) was used as control. The
ells were maintained for 6 days and HIV p24 antigen production was
easured. Vertical bars represent the SD of the average (plotted as
illed squares or filled diamonds) of three p24 determinations.pounds (Nagy et al., 1994). We constructed a replication-
competent recombinant HIV, Z6 D nef gpt, that expressesthe E. coli gpt gene under the control of the viral LTR
promoter, yet lacks a competent nef gene. This virus can
induce the expression of the bacterial enzyme GPT in
PM-1 cells and simultaneously transduce the MPA resis-
tance and the susceptibility to 6-TX.
The deletion of key accessory genes such as nef has
been a common approach for generating attenuated HIV
strains. Daniel and colleagues (1992) and others (Al-
mond et al., 1995) found that, although deletion of SIV nef
in rhesus monkeys had little or no effect on in vitro
replication, infection with SIV nef (2) strains in vivo
resulted in low-level viremia without development of dis-
ease. Moreover, the animals were protected against
challenge with wild-type virus several years later (Al-
mond et al., 1995). The monkey model shows that the SIV
vaccine deleted in nef has an attenuated phenotype that
is stable, even though a functional nef provides a tre-
mendous selective advantage in vivo. In adults, deletion
of nef results in at least a two-log reduction in the virus
load (Kestler et al., 1991). On the other hand, deletion of
vpr and other accessory genes does not appear to yield
the attenuated phenotype in the monkey model (Gibbs et
al., 1995) or SCID mice (Aldrovandi and Zack, 1996). The
nef gene also seems to be implicated in HIV pathogen-
esis in humans and a large number of viruses carrying
defective or deleted nef alleles were systematically re-
covered from four long-term nonprogressing survivors of
HIV-1 infection (Mariani et al., 1996).
Our findings with the Z6 D nef gpt recombinant dem-
nstrate a high genetic stability for the gpt marker in a
etroviral framework, specifically using HIV Z6 as the
ackbone of the infectious molecular clone. A recent
eport has shown that an HIV-1 genome carrying the
DNA of a proteolysis-resistant NF-kB inhibitor in the nef
region downregulates viral expression and is highly at-
tenuated in both Jurkat and peripheral blood mononu-
clear cells. This recombinant virus maintains the exoge-
nous insert, despite 180 days of forced ex vivo passaging
in tissue culture (Quinto et al., 1999). In contrast, recom-
binant SIV carrying the human interferon gene in the nef
coding region was highly unstable, losing the inserted
DNA in 14 days during the culture without selective
pressure (Giavedoni and Yilma, 1995). In our study, the
gpt marker was stable for more than 45 days in contin-
uous passage. Perhaps the gpt gene does not interfere
with the replication of HIV or increases the intracellular
purine salvage pathway, thus giving the cells a selective
advantage. HIV infection in lymphocytes depletes the
intracellular pool of guanine (Bofil et al., 1995; Carlucci et
al., 1996). The enhancement in the purine salvage in-
duced with the E. coli gpt expression could antagonize
the viral effect in this important cellular metabolic path-
way.
The introduction of the E. coli gpt gene converted
HIV-1 into a 6-TX-sensitive virus through subsequent
metabolization of this analog by GPT. Treatment with
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83IN VIVO SELECTABLE HIV-16-TX can inhibit PM-1 cells harboring the Z6 D nef gpt
provirus as well as the productive replication in PBMCs.
Therefore, our experimental data clearly show that rep-
lication of the Z6 D nef gpt could be suppressed using a
negative selective drug (6-TX).
We have demonstrated the replacement of the HIV nef
gene with a functional E. coli gpt gene. Such an ap-
proach was previously found to be successful using a
gpt retroviral vector to transduce the 6-TX susceptibility
to murine sarcoma cells. Systemic 6-TX therapy induced
durable regressions in mice previously implanted with
gpt-positive K3T3 sarcoma cells. A similar approach was
also used in a nude-mouse model of intracerebral tu-
mors: grafting gpt-retrovirus-producing cells led to an
80% reduction in intracerebral tumor volumes and a 28%
increase in the mean survival time of animals after 6-TX
treatment (Mroz and Moolten, 1993; Ono et al., 1997). Our
findings indicate that HIV-gpt recombinants hold promise
for an alternative live-attenuated HIV-1 vaccine like
HIV-tk (Chakrabarti et al., 1996; Smith et al., 1996). Further
studies using animal models such as hu-PBMC-SCID
mouse and HIV-2/SIV infected macaques should be done
to ensure the efficacy of 6-TX treatment in abrogating the
Z6 D nef gpt in vivo. Conceptually, such an approach
could provide a means to formulate alternative, safer,
live-attenuated HIV vaccines that carry a selectable “sui-
cide” gene.
MATERIALS AND METHODS
Construction of Z6 D nef gpt
To replace the nef gene of Z6 infectious clone with the
E. coli gpt gene, we developed a new cloning strategy,
which combines PCR technology with the resistance of
phosphothioate bonds to the 59–39 double-strand-spe-
cific T7 exonuclease digestion (Kerr and Sadowski, 1972;
Nikiforov et al., 1994). Primers used to amplify the DNA
target regions being manipulated presented three phos-
phothioate bonds at the fifteenth base from the 59 end.
When the amplification products were digested with T7
exonuclease, the hydrolytic T7 Exo activity continued
through the 59 end until it reached the phosphothioate
bonds, generating a short, single-strand DNA tail, which
contains the nucleotide integrity of the 39 strand. Two
independently amplified products of contiguous se-
quences can regenerate into a stable recombinant struc-
ture when further combined in the same reaction tube in
the presence of T4 DNA ligase.
The overall approach is outlined in Fig. 7. The goal
was to replace the 59 half of the nef gene of the Z6 clone
with the entire coding sequence of the E. coli gpt gene
carried by pMSG (Lee et al., 1981). The pBR322 infectious
clone of HIV-1 Z2Z6 (subtype D) (Srinivasan et al., 1987)
was digested with EcoRI. A resulting 4-kb fragment con-
tained the 39 end of the HIV genome, including the nef
gene (Fig. 7A, Step 1). A 6-kb fragment, encompassingthe vector backbone and the HIV insert minus the 248 bp
representing the 59 half of the nef gene, was amplified
using pUC-NEF as a template (Fig. 7A, Step 2). Condi-
tions for PCR amplifications were as described in the XL
PCR kit (Perkin–Elmer, Branchburg, NJ) using 20 pmol of
primers gp41RC (ATGTTAAAGCAAsAsAsGCCTTTCTA-
AGCCCTGT; “s” denotes phosphothioate bonds) and
nefF1 (ACTTACAAAGGAGsCsGsTTAGATCTTAGCCACT).
The cycling conditions were as follows: 16 cycles of
denaturation at 94°C for 2 min and elongation at 60°C for 6
min each, followed by 25 cycles of denaturation at 94°C for
2 min and elongation at 68°C for 6 min each. Another
458-bp fragment, containing the entire E. coli gpt gene, was
amplified using vector pMSG as a template. The reactions
were carried out with 0.2 mM of each dNTP, 2.5 mM of
MgCl2, 20 pmol of primers gptF2C (59-TTTTGCTTTAACsAs-
sGGCCGAAAAATACATCGTCA-39; the GC sequence in
old in oligo gptF2 represents a mutation site included in
his oligo.) and gptR2 (59-TCCTTTGTAAGTTsTsAsGCGAC-
GGAGATTGGCGGGAC-39), 2.5 U of Taq polymerase from
erkin–Elmer Cetus Instruments (Norwalk, CT) and 1X re-
ction buffer. The reactions were subjected to three cycles
f 94°C for 15 s, 55°C for 1 min, and 72°C for 1 min,
ollowed by 32 cycles of 94°C for 30 s, 55°C for 30 s, and
2°C for 1 min, and a final extension of 72°C for 5 min.
The PCR products were purified using Qiagen Qia-
uick Spin PCR Purification Kit (Qiagen, Chatsworth, CA)
ollowing the standard protocol. To generate the single-
trand 39 end of each amplified fragment, T7 Exo enzyme
as added to a final concentration of 2 U/mg of PCR
product. The reaction was incubated for 1 h at room
temperature. Reaction tubes were placed at 70°C for 10
min to inactivate the enzyme (Fig. 7A, Step 3). The T7
Exo-digested pUCnef and E. coli gpt gene were com-
ined in a single tube with a 5:1 ratio of insert to vector
nd T4 DNA ligase was added according to the manu-
acturer’s protocols (Rapid DNA Ligation Kit; Boehringer-
annheim, Indianapolis, IN). One tenth of this ligation
eaction was used to transform E. coli MAX efficiency
H5a-competent cells (GIBCO-BRL, Gaithersburg, MD),
ollowed by plating on ampicillin/kanamycin-containing
lates (Fig. 7A, Step 4). The plasmid DNA from the
olonies was isolated and screened by PCR, using nef1
nd nef2 primers (data not shown). This clone was
amed pUC D nef gpt. The construction was confirmed
y automated DNA sequencing. The full-length clone
as regenerated through partial digestion of the Z6
lone and isolation of a 9.7-kb fragment containing all
equences, except for the 4.0-kb fragment, which was
onated by the pUC D nef gpt. These two fragments were
ligated, transformed in E. coli MAX efficiency DH5-com-
petent cells (GIBCO-BRL), and plated on ampicillin/kana-
mycin-containing plates (Fig. 7A, Steps 5 and 6). The nef
gene overlapping the 39 LTR sequences was preserved
to avoid disturbing the viral replicative function located in
that piece of the genome. The 248-pb 59 half of the nef
84 TANURI ET AL.
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85IN VIVO SELECTABLE HIV-1gene extending from the first ATG codon to the 82nd
codon was deleted and replaced by a 458-bp fragment
that represented the entire coding sequence of the E.
coli gpt gene. The nef deletion prevented reversion of the
gene and accommodated the larger gpt gene insert with-
ut greatly increasing the net size of HIV genome. The
acterial gene was manipulated by changing its original
econd codon AGC to GCC, to follow the Kozak transla-
ion initiation sequence, thus ensuring an efficient trans-
ation (Kozak, 1987). In this case, the E. coli gpt gene can
be expressed using the same promoter and splicing
signal as the original HIV nef gene. This infectious clone
as named Z6 D nef gpt (see Fig. 7B).
A nef (2) genome control was also constructed for
iological characterization of the Z6 D nef gpt virus. The
IV Z6 infectious clone was partially digested with XhoI,
nd the linear fragment was isolated from agarose gel.
his fragment was blunt-ended by incubating it with Pfu
NA pol and a 0.2 mM dNTP mix at 72°C for 30 min. The
lasmid was ligated with T4 DNA ligase and transformed
n E. coli DH5a-competent cells. Clones were selected
by XhoI digestion, and those clones lacking one XhoI site
(position 8890 in HIV Z6 genome) were sequenced to
confirm the 4-bp insertion in the coding sequence of the
nef gene, disrupting its reading frame. This infectious
clone was named HIV Z6 fsnef.
Virus and cells
PM-1 was maintained in RPMI 1640 media supple-
mented with 10% fetal calf serum (FCS) and in selective
media. Two different selective media were used: MHX
(RPMI 10% FCS; MPA in variable concentrations, ranging
from 0 to 10 mg/ml; xanthine 200 mg/ml; and hypoxan-
thine 25 mg/ml) for positive selection and 6-TX (RPMI 10%
FCS; 6-thioxanthine in variable concentrations, ranging
from 0 to 100 mg/ml) for negative selection. During se-
ection, fresh media was added every 3 days to account
or the half-life of their components. PBMCs were pre-
ared from HIV-seronegative donors by Ficoll separation,
ashed in PBS, and stimulated in RPMI 1640 containing
0% FCS, 1% penicillin-streptomycin, L-glutamine, and
upplemented with 10 units/ml interleukin-2 and 4 mg/ml
phytohemagglutinin-P (PHA). Cells were incubated for
48 h, and supernatant was removed and replaced with
medium without PHA but with 10 units/ml of interleukin-2,
during replacement experiments with positive (MPA) and
negative (6-TX) selection.
HIV-Z6, HIV Z6 D nef gpt, and HIV Z6 fs nef molecular
lones were generated through transfection in COS-7
FIG. 7. Schematic representation of the new cloning strategy (A) an
annealing positions of the primers nef 102 and nef 103 (B). In (A), the
arrows represent the oligonucleotides used as thio-primers for pMSG-gpt a
different shades of black and gray.ells (2 3 105 cells in a 35-mm plate) with 1 mg of purified
lasmid using the lipofectamin standard protocol (Gibco-
RL, Grand Island, NY). The viruses generated in these
ransfections were further used to infect PM-1 cells and
BMCs. The multiplicity of infection (m.o.i.) was stan-
ardized for HIV Z6 clones and for derivatives related to
24 antigen concentration (104 TCID50 5 1 ng of p24).
he viral replication was followed with HIV p24/gag an-
igen determination with reagents from Coulter (Hialeah,
L). The PM-1 cell viability was determined by Trypan
lue exclusion.
xpression of gpt in infected cells
PM-1 cells were infected with Z6, Z6 fsnef, and Z6 Dnef
gpt at a m.o.i. of 0.1. At different times postinfection, 107
PM-1 cells were lysed with RIPA buffer (10 mM Tris–HCl,
pH 7.5; 150 mM NaCl; 5 mM EDTA; 1% NaDOC; 1% Triton
X-100; 1% SDS; 10 mg/ml aprotinin; 2 mg/ml leupeptin; 2
mg/ml benzamidine; 10 mg/ml TLCK; and 0.2 mM PMSF),
and the total protein was biotinylated and immunopre-
cipitated using the cellular labeling and immunoprecipi-
tation kit according to the protocol provided by the man-
ufacturer (Boehringer-Manheim). The labeled protein
was immunoprecipitated with a 1:500 dilution of a poly-
clonal rabbit antibody directed against a KLH-linked syn-
thetic peptide (KGIIAVSRGGLVPGA) representing the
GPT protein (residues 28 to 43). The final immunopre-
cipitated protein was analyzed in a 4–20% gradient SDS–
PAGE gel (Novex, San Diego, CA). The gel was electro-
transferred onto PVDF membrane using a Bio-Rad Mini
trans-blot cell (Bio-Rad) under conditions described by
the manufacturer. The membrane was blocked and de-
tected by chemiluminescence (Boehringer-Mannheim).
PCR determination of proviral gpt
Total cellular DNA was extracted using the QIAamp
blood kit (Qiagen). Primers nef 102 and nef 103 were
used to amplify proviral DNA. This pair of primers ampli-
fies the entire HIV-1 nef gene, producing a 934-bp am-
plicon with HIV Z6 and HIV Z6 fsnef and a 1134-bp
amplicon with HIV Z6 D nef gpt. Taq polymerase was
obtained from Perkin–Elmer Cetus and used according
to the manufacturer’s recommendations: 0.2 mM of each
dNTP, 25 pmol of each primer, and 2.5 mM of MgCl2 were
combined in the 100-ml reaction mixture. Cycling condi-
tions were 94°C for 2 min, followed by 35 cycles of 94°C
for 1 min, 55°C for 1 min, and 72°C for 2 min.
mic structure of proviral molecules used in the experiments, showing
reas of HIV-carrying constructs represent non-HIV sequences. Larged geno
gray and pUC-nef amplification, with their complementarity represented by
AC
C
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